Table 4.
Exhaustiveness of PRFs selected through the Delphi survey in medical records of older individuals with dementia.
| Indicators | Exhaustiveness of medical records | ||
|---|---|---|---|
| n | % | Description* | |
| Haloperidol (n = 9) | |||
| Age | 0 | 0.0 | High |
| Hepatic function | 2 | 22.2 | Low |
| Comorbidities | 0 | 0.0 | High |
| EKG | 4 | 44.4 | Low |
| Electrolyte disturbances | 0 | 0.0 | High |
| Co-medications | 0 | 0.0 | High |
| Labeled indication | 0 | 0.0 | High |
| Frailty/risk of falls | n/a | n/a | n/a |
| Previous ADRs | n/a | n/a | n/a |
| Cognitive status | 6 | 66.7 | Low |
| Benefit-risk ratio assessment | n/a | n/a | n/a |
| Presence of Parkinson Disease | 0 | 0.0 | High |
| Olanzapine (n = 23) | |||
| Age | 0 | 0.0 | High |
| Renal function | 3 | 12.5 | Medium |
| Hepatic function | 7 | 30.4 | Low |
| Comorbidities | 0 | 0.0 | High |
| Co-medications | 0 | 0.0 | High |
| Presence of hyperglycaemia | 6 | 26.1 | Low |
| Presence of diabetes mellitus | 0 | 0.0 | High |
| Weight | 23 | 100.0 | Low |
| Cardiovascular risk | n/a | n/a | n/a |
| Labeled indication | 0 | 0.0 | High |
| Frailty/Risk of falls | n/a | n/a | n/a |
| Previous ADRs | n/a | n/a | n/a |
| Cognitive status | 14 | 60.9 | Low |
| Benefit-risk ratio assessment | n/a | n/a | n/a |
| Cerebrovascular risk | n/a | n/a | n/a |
| Risperidone (n = 29) | |||
| Age | 0 | 0.0 | High |
| Renal function | 2 | 6.9 | Medium |
| Hepatic function | 5 | 17.2 | Low |
| Comorbidities | 0 | 0.0 | High |
| Co-medications | 0 | 0.0 | High |
| Presence of hyperglycaemia | 3 | 10.3 | Medium |
| Presence of diabetes mellitus | 0 | 0.0 | High |
| Weight | 29 | 100.0 | Low |
| Cardiovascular risk | n/a | n/a | n/a |
| Labeled indication | 0 | 0.0 | High |
| Frailty/risk of falls | n/a | n/a | n/a |
| Previous ADRs | n/a | n/a | n/a |
| Cognitive status | 12 | 41.4 | Low |
| Benefit-risk ratio assessment | n/a | n/a | n/a |
| Cerebrovascular risk | n/a | n/a | n/a |
| Quetiapine (n = 33) | |||
| Age | 0 | 0.0 | High |
| Hepatic function | 10 | 30.3 | Low |
| Comorbidities | 0 | 0.0 | High |
| EKG | 14 | 42.4 | Low |
| Co-medication | 0 | 0.0 | High |
| Cardiovascular risk | n/a | n/a | n/a |
| Blood pressure | 4 | 12.1 | Medium |
| Labeled indication | 0 | 0.0 | High |
| Frailty/risk of falls | n/a | n/a | n/a |
| Previous ADRs | n/a | n/a | n/a |
| Cognitive status | 26 | 78.8 | Low |
| Benefit-risk ratio assessment | n/a | n/a | n/a |
| Cerebrovascular risk | n/a | n/a | n/a |
| Aripiprazole (n = 6) | |||
| Age | 0 | 0.0 | High |
| Comorbidities | 0 | 0.0 | High |
| Co-medications | 0 | 0.0 | High |
| Cardiovascular risk | n/a | n/a | n/a |
| Labeled indication | 0 | 0.0 | High |
| Benefit-risk ratio assessment | n/a | n/a | n/a |
| Cerebrovascular risk | n/a | n/a | n/a |
| Clinical response and tolerability to previous APs | n/a | n/a | n/a |
EKG, electrocardiogram; n/a, not available.
*
High exhaustiveness: <1% missing values; medium exhaustiveness: between 1 and 15%; low exhaustiveness: >15% missing values).